Transcend Capital Advisors LLC Has $3.49 Million Stake in Pfizer Inc. (NYSE:PFE)

Transcend Capital Advisors LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 91.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 121,277 shares of the biopharmaceutical company’s stock after buying an additional 57,988 shares during the period. Transcend Capital Advisors LLC’s holdings in Pfizer were worth $3,492,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of PFE. Briaud Financial Planning Inc acquired a new stake in shares of Pfizer in the third quarter valued at approximately $30,000. Mizuho Securities Co. Ltd. bought a new position in shares of Pfizer during the third quarter worth $34,000. VisionPoint Advisory Group LLC boosted its position in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC boosted its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in Pfizer in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a report on Thursday, January 4th. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $36.33.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.14 on Friday, reaching $25.40. 46,526,457 shares of the stock were exchanged, compared to its average volume of 34,120,812. The firm’s 50 day moving average is $26.96 and its 200-day moving average is $28.42. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market cap of $143.83 billion, a PE ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the prior year, the firm posted $1.14 EPS. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.61%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.